<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Second-degree atrioventricular block: Mobitz type II</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Second-degree atrioventricular block: Mobitz type II</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Second-degree atrioventricular block: Mobitz type II</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William H Sauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomic or functional impairment in the conduction system. The conduction disturbance can be transient or permanent, with conduction that is delayed, intermittent, or absent. Commonly used terminology includes:</p><p class="bulletIndent1"><span class="glyph">●</span>First-degree AV block – Delayed conduction from the atrium to the ventricle (defined as a prolonged PR interval of &gt;200 milliseconds) without interruption in atrial to ventricular conduction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Second-degree AV block – Intermittent atrial conduction to the ventricle, often in a regular pattern (eg, 2:1, 3:2), or higher degrees of block, which are further classified into Mobitz type I (Wenckebach) and Mobitz type II second-degree AV block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Third-degree (complete) AV block – No atrial impulses conduct to the ventricle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-grade AV block – Two or more consecutive blocked P waves.</p><p></p><p>The clinical presentation, evaluation, and management of Mobitz type II second-degree AV block will be reviewed here. The etiology of AV block in general, and the management of other specific types of AV block, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/913.html" rel="external">"First-degree atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block"</a>.)</p><p class="headingAnchor" id="H125048228"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>In second-degree AV block, some atrial impulses fail to reach the ventricles. Wenckebach described progressive delay between atrial and ventricular contraction and the eventual failure of a P wave to conduct to the ventricles [<a href="#rid1">1</a>]. Mobitz subsequently divided second-degree AV block into two subtypes, as determined by the findings on the electrocardiogram (ECG) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mobitz type I second-degree AV block  (<a class="graphic graphic_waveform graphicRef73051" href="/z/d/graphic/73051.html" rel="external">waveform 1</a>), in which progressive PR interval prolongation precedes a nonconducted P wave. The first P wave after block conducts to the ventricle with a shorter PR interval compared with the last P wave before block.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mobitz type II second-degree AV block  (<a class="graphic graphic_waveform graphicRef58649" href="/z/d/graphic/58649.html" rel="external">waveform 2</a>), in which the PR interval remains unchanged prior to a P wave that fails to conduct to the ventricles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-grade AV block, in which two or more consecutive P waves are nonconducted. In contrast to third degree (complete) AV block  (<a class="graphic graphic_waveform graphicRef72863" href="/z/d/graphic/72863.html" rel="external">waveform 3</a>), however, some P waves continue to be conducted to the ventricle.</p><p></p><p>Mobitz type I and Mobitz type II second-degree AV block cannot be differentiated from the ECG when 2:1 AV block is present. In this situation, every other P wave is nonconducted and there is no opportunity to observe for the constant PR interval that is characteristic of Mobitz type II second-degree AV block. (See <a class="local">'ECG findings'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The potential etiologies of Mobitz type II second-degree AV block include reversible and irreversible conditions (pathologic, iatrogenic, and idiopathic) that are similar to other degrees of AV block  (<a class="graphic graphic_table graphicRef62885" href="/z/d/graphic/62885.html" rel="external">table 1</a>). Common causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic – Myocardial ischemia (acute or chronic) involving the conduction system, cardiomyopathy (eg, amyloidosis, sarcoidosis), myocarditis (eg, Lyme disease), endocarditis with abscess formation, hyperkalemia, and hypervagotonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic – Medication-related (AV nodal blocking medications), post-cardiac surgery, post-catheter ablation, post-transcatheter aortic valve implantation.</p><p></p><p>Mobitz type II second-degree AV block is rarely seen in patients without underlying heart disease. When identifiable, the reversible causes most commonly associated with Mobitz type II second-degree AV block are myocardial infarction with ischemia of the AV node and medications that alter conduction through the AV node (eg, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, beta blockers, calcium channel blockers). When no specific reversible cause is identified, the block is often felt to be related to idiopathic progressive cardiac conduction disease with myocardial fibrosis and/or sclerosis that affects the conduction system. (See  <a class="medical medical_review" href="/z/d/html/944.html" rel="external">"Cardiac arrhythmias due to digoxin toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a>.)</p><p class="headingAnchor" id="H125049903"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Mobitz type II second-degree AV block almost always results from conduction system disease below the level of the AV node  (<a class="graphic graphic_figure graphicRef63340" href="/z/d/graphic/63340.html" rel="external">figure 1</a>), occurring in the bundle of His in approximately 20 percent of cases and in the bundle branches in the remainder [<a href="#rid3">3</a>]. Patients with bundle branch involvement also have axis shifts and QRS widening depending upon the location of the block. In addition, at least two-thirds of patients with this disorder also have bifascicular or even trifascicular disease [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2101.html" rel="external">"Basic approach to delayed intraventricular conduction", section on 'Bifascicular and trifascicular block'</a> and  <a class="medical medical_review" href="/z/d/html/1063.html" rel="external">"Chronic bifascicular blocks"</a>.)</p><p class="headingAnchor" id="H125048527"><span class="h1">CLINICAL PRESENTATION AND EVALUATION</span><span class="headingEndMark"> — </span>The clinical presentation of Mobitz type II second-degree AV block is variable depending upon the underlying sinus rhythm heart rate, the frequency of nonconducted P waves, and the presence of comorbid conditions. The evaluation of all patients with suspected Mobitz type II second-degree AV block includes a thorough history, including medications and recent changes in medications, along with a 12-lead ECG and bloodwork (which includes serum electrolytes and thyroid-stimulating hormone [TSH]).</p><p class="headingAnchor" id="H125048600"><span class="h2">Etiology and reversible causes</span><span class="headingEndMark"> — </span>All patients with suspected Mobitz type II second-degree AV block should be questioned about any history of heart disease, both congenital and acquired, as well as any recent cardiac procedures or medications that could predispose to AV conduction abnormalities. Patients without known cardiac disease should be questioned about other systemic diseases associated with heart block (eg, amyloidosis, sarcoidosis). Patients who live in an area with endemic Lyme disease should be questioned about any recent outdoor exposure to ticks or known tick bites. (See <a class="local">'Etiology'</a> above.)</p><p>Patients with suspected Mobitz type II second-degree AV block that occurs in the setting of acute myocardial ischemia or infarction should undergo concurrent diagnosis and treatment for both conditions. (See  <a class="medical medical_review" href="/z/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction", section on 'Management of conduction abnormalities'</a>.)</p><p>Patients should provide a full list of medications and be questioned about any recent changes in dosing, with particular attention paid to drugs that alter AV nodal conduction (ie, beta blockers, nondihydropyridine calcium channel blockers, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, select antiarrhythmic drugs).</p><p>In patients under 60 years of age who present with otherwise unexplained heart block, previously undetected cardiac sarcoidosis has been identified in up to 25 to 35 percent of patients [<a href="#rid6">6,7</a>]. Such patients with otherwise unexplained complete heart block should be evaluated for cardiac sarcoidosis [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p class="headingAnchor" id="H125048780"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Most patients with Mobitz type II second-degree AV block will present with some degree of symptoms, though the severity of the symptoms can be quite variable. Symptoms may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue </p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Presyncope or syncope</p><p class="bulletIndent1"><span class="glyph">●</span>Sudden cardiac arrest</p><p></p><p>Mobitz type II second-degree AV block with only infrequent nonconducted P waves in a patient with a normal sinus heart rate (ie, 60 to 100 beats per minute) may produce few or no symptoms. However, if the patient has sinus bradycardia at baseline, or there are more frequent nonconducted beats, there may be a significant reduction in cardiac output resulting in symptoms of hypoperfusion or heart failure.</p><p>The failure of one or more P waves to conduct to the ventricles can lead to fatigue, lightheadedness, presyncope, or syncope (called Stokes-Adams attacks) since the lower intrinsic cardiac pacemakers are slower than junctional pacemakers  (<a class="graphic graphic_waveform graphicRef64261" href="/z/d/graphic/64261.html" rel="external">waveform 4</a>) [<a href="#rid9">9-12</a>].</p><p>Patients with Mobitz type II second-degree AV block often present with bradycardia but may have a normal sinus rhythm rate. Additionally, other than the presence of an irregular pulse, there are few specific physical examination findings. Patients may appear pale or diaphoretic if they have bradycardia with a resultant reduction in cardiac output. Patients with underlying heart failure that is exacerbated by the development of heart block may have crackles on lung examination, elevated jugular venous pulsations, and/or peripheral edema.</p><p class="headingAnchor" id="H125048864"><span class="h2">ECG findings</span><span class="headingEndMark"> — </span>Mobitz type II second-degree AV block is identified by consistent unchanging PR intervals (which are usually normal in duration but may be prolonged) followed by the block of one or more P waves that fail to conduct to the ventricles  (<a class="graphic graphic_waveform graphicRef79539" href="/z/d/graphic/79539.html" rel="external">waveform 5</a>).</p><p>Mobitz type II second-degree AV block is distinguished from other types of AV block as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with first degree AV block have a PR interval that is prolonged (&gt;200 milliseconds) but constant, and each P wave is followed by a QRS interval  (<a class="graphic graphic_waveform graphicRef67882" href="/z/d/graphic/67882.html" rel="external">waveform 6</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Mobitz type I second-degree AV block have progressive prolongation of the PR interval for several heart beats, followed by a nonconducted P wave  (<a class="graphic graphic_waveform graphicRef73051" href="/z/d/graphic/73051.html" rel="external">waveform 1</a>). For patients with second-degree AV block with a ratio of atrial to ventricular conduction that is not 2:1, Mobitz type I and Mobitz type II second-degree AV block are easily distinguished. However, for patients with 2:1 atrial to ventricular conduction, the distinction between Mobitz type I and Mobitz type II second-degree AV block cannot be made from the surface ECG. (See  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)", section on 'ECG findings and diagnostic maneuvers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with third degree (complete) AV block will have evidence of atrial (P waves) and ventricular (QRS complexes) activity that are independent of each other on the surface ECG  (<a class="graphic graphic_waveform graphicRef72863" href="/z/d/graphic/72863.html" rel="external">waveform 3</a>). In rare instances, the atrial rate may be exactly twice the ventricular rate, resulting in 2:1 AV block which can mimic second-degree AV block.</p><p></p><p>An increase in heart rate due to exercise, <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>, or atrial pacing can worsen Mobitz type II second-degree AV block. Conversely, vagal maneuvers may slow the sinus rate, allow more time for excitability to recover in or below the bundle of His, thereby facilitating conduction across the AV node and improving Mobitz type II second-degree AV block. (See  <a class="medical medical_review" href="/z/d/html/909.html" rel="external">"Second-degree atrioventricular block: Mobitz type I (Wenckebach block)", section on 'ECG findings and diagnostic maneuvers'</a>.)</p><p class="headingAnchor" id="H2169405"><span class="h2">Electrophysiology study</span><span class="headingEndMark"> — </span>Electrophysiology studies (EPS) performed for an evaluation of a suspected arrhythmia or when there is a question about the level of block leading to bradycardia can reveal intracardiac evidence of infra-Hisian block. In addition, an EPS may identify patients with Mobitz type II second-degree AV block who are at increased risk of progression to third degree (complete) heart block. However, since nearly all patients without a readily identifiable reversible cause are candidates for a permanent pacemaker, EPS is of limited value and not usually performed [<a href="#rid13">13</a>]. There is a 2017 case report that describes the successful treatment of second-degree AV block with catheter ablation of a ventricular nodal pathway manifesting as concealed and manifest junctional beats. In this very rare circumstance where concealed junctional extrasystoles are suspected, an EPS and possible ablation may be considered [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p>His bundle electrocardiography, performed as part of an invasive EPS, shows that the nonconducted A wave (P wave on surface ECG) is followed by a His deflection, and not infrequently, a split His potential due to slowed intra-Hisian conduction  (<a class="graphic graphic_waveform graphicRef79539" href="/z/d/graphic/79539.html" rel="external">waveform 5</a>). Rarely, proximal His block does not demonstrate a His potential with the nonconducted A wave (P wave on the surface ECG), falsely suggesting that the block is in the AV node [<a href="#rid3">3,15,16</a>].</p><p class="headingAnchor" id="H125048993"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In nearly all cases, the diagnosis of Mobitz type II second-degree AV block can be made in a patient with an irregular pulse or suggestive symptoms (eg, fatigue, dyspnea, presyncope, and/or syncope) by obtaining a surface ECG. (See <a class="local">'ECG findings'</a> above.)</p><p>For patients with 2:1 AV block in whom the distinction between Mobitz type I and Mobitz type II second-degree AV block cannot be made using the surface ECG alone, a long rhythm strip should be obtained or a previous ECG examined to try to find evidence of constant PR intervals preceding a nonconducted P wave, as well as to identify nonconducted P waves in a pattern other than 2:1 (eg, 3:2, 4:3, etc) that would suggest Mobitz type I second-degree AV block. Additionally, carotid sinus massage may be performed, or intravenous <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> administered in those patients where carotid sinus massage may be unwanted because of concern for vascular disease, to help distinguish the level of AV block. If the diagnosis remains uncertain following these measures, invasive electrophysiology studies can definitively diagnose the type of AV block and accurately identify the level of the block.</p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1358395304"><span class="h2">Initial management</span><span class="headingEndMark"> — </span>The initial management of the patient with Mobitz type II second-degree AV block depends on the presence and severity of any signs and symptoms related to the ventricular rate  (<a class="graphic graphic_algorithm graphicRef140931" href="/z/d/graphic/140931.html" rel="external">algorithm 1</a>). Unstable patients require immediate pharmacologic therapy and, in most instances, should also receive temporary pacing to increase heart rate and cardiac output. </p><p class="headingAnchor" id="H125049064"><span class="h3">Unstable patients</span><span class="headingEndMark"> — </span>Patients with Mobitz type II second-degree AV block who are hemodynamically unstable should be urgently treated with a beta-adrenergic agonist (eg, <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a>, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>) if myocardial ischemia is unlikely [<a href="#rid13">13</a>] and, in most instances, with temporary cardiac pacing (either with transcutaneous or, if immediately available, transvenous pacing). <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">Atropine</a> is generally avoided in patients with Mobitz type II second-degree AV block, as the block is generally infranodal. Rarely, atropine or other agents can worsen infranodal block by increasing sinus rate without improving conduction.</p><p>Signs and symptoms of hemodynamic instability include hypotension, altered mental status, signs of shock, ongoing ischemic chest pain, and evidence of acute pulmonary edema. <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">Dopamine</a> may be administered in hypotensive patients, while <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> is an option for patients with heart failure symptoms. This approach is similar to the patient who presents with unstable third degree (complete) AV block. (See  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Bradycardia'</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block", section on 'Unstable patients'</a>.)</p><p class="headingAnchor" id="H125049071"><span class="h3">Stable patients</span><span class="headingEndMark"> — </span>Patients with Mobitz type II second-degree AV block who are hemodynamically stable do not require urgent therapy with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or temporary cardiac pacing. However, Mobitz type II second-degree AV block is by nature unstable and frequently progresses to third degree (complete) AV block, so patients should be continuously monitored with transcutaneous pacing pads in place in the event of clinical deterioration. In addition, most stable patients continue to have symptoms related to the bradycardia and will require identification and treatment of any reversible causes or permanent therapy with an implantable pacemaker.</p><p class="headingAnchor" id="H2876879683"><span class="h2">Further management</span><span class="headingEndMark"> — </span>Once unstable patients have been stabilized, and while stable patients are being monitored, reversible causes of Mobitz type II second-degree AV block such as myocardial ischemia, increased vagal tone, hypothyroidism, hyperkalemia, and drugs that depress conduction should be addressed prior to determining whether implantation of a permanent pacemaker is required  (<a class="graphic graphic_algorithm graphicRef140930" href="/z/d/graphic/140930.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Mobitz type II second-degree AV block in the setting of an acute myocardial infarction should be treated with temporary pacing and revascularization; following revascularization, most conduction abnormalities will improve or resolve and will not require permanent pacing. (See  <a class="medical medical_review" href="/z/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Mobitz type II second-degree AV block felt to be medication-induced should be observed while the offending agent or agents are withdrawn; such patients will often have improvement or resolution of AV block following removal of the medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Mobitz type II second-degree AV block in the setting of hyperkalemia should receive therapy to reduce serum potassium levels; similarly, patients with hypothyroidism should receive thyroid replacement therapy. If Mobitz type II second-degree AV block subsequently resolves, a permanent pacemaker is not usually needed. (See  <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">"Treatment and prevention of hyperkalemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Lyme carditis and associated heart block frequently do not require permanent cardiac pacing. Mobitz type II second-degree AV block typically improves to lesser degrees of AV block within one week, and more minor conduction disturbances usually resolve within six weeks. As such, while these patients may initially require temporary cardiac pacing, permanent cardiac pacing should be reserved for patients with persistent high grade AV block following an adequate course of therapy for Lyme disease. (See  <a class="medical medical_review" href="/z/d/html/7915.html" rel="external">"Lyme carditis"</a>.)</p><p></p><p>If no reversible causes are present, definitive treatment of Mobitz type II second-degree AV block involves permanent pacemaker placement in most patients [<a href="#rid13">13,17</a>]. Dual-chamber (ie, atrioventricular) pacing to maintain AV synchrony is preferred (rather than single chamber right ventricular pacing) in most patients due to the favorable hemodynamic benefits of AV synchrony  (<a class="graphic graphic_algorithm graphicRef71370" href="/z/d/graphic/71370.html" rel="external">algorithm 3</a>). Unlike asymptomatic patients with Mobitz type I second-degree AV block who do not require any specific therapy, patients with Mobitz type II second-degree AV block have a high likelihood of progressing to symptomatic Mobitz type II second-degree AV block or complete heart block and should be considered candidates for pacemaker insertion on initial presentation [<a href="#rid13">13,18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/941.html" rel="external">"Permanent cardiac pacing: Overview of devices and indications", section on 'Acquired AV block'</a> and  <a class="medical medical_review" href="/z/d/html/950.html" rel="external">"Modes of cardiac pacing: Nomenclature and selection"</a>.)</p><p class="headingAnchor" id="H2969077756"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H17479459"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16936.html" rel="external">"Patient education: Bradycardia (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/17118.html" rel="external">"Patient education: Heart block in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2169553"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomic or functional impairment in the conduction system. In second-degree AV block, some atrial impulses fail to reach the ventricles.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In Mobitz type I second-degree AV block, there is progressive PR interval prolongation for several beats preceding a nonconducted P wave. (See <a class="local">'Introduction'</a> above and <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In Mobitz type II second-degree AV block, the PR interval remains unchanged prior to a P wave that suddenly fails to conduct to the ventricles  (<a class="graphic graphic_waveform graphicRef79539" href="/z/d/graphic/79539.html" rel="external">waveform 5</a>). (See <a class="local">'ECG findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The potential etiologies of Mobitz type II second-degree AV block include reversible and irreversible conditions (pathologic, iatrogenic, and idiopathic) that are similar to other degrees of AV block  (<a class="graphic graphic_table graphicRef62885" href="/z/d/graphic/62885.html" rel="external">table 1</a>). Common potentially reversible causes include myocardial ischemia and medications. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1">All patients with suspected Mobitz type II second-degree AV block should be questioned about any history of heart disease, both congenital and acquired, as well as any recent cardiac procedures or medications that could predispose to AV conduction abnormalities. (See <a class="local">'Etiology and reversible causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients with Mobitz type II second-degree AV block will present with some degree of symptoms, though the severity of the symptoms can be quite variable. Symptoms may include fatigue, dyspnea, chest pain, presyncope, syncope, or sudden cardiac arrest. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of patients with Mobitz type II second-degree AV block depends on the presence or absence of symptoms, the hemodynamic status of the patient, the response to initial therapy, and the identification of any potentially reversible causes  (<a class="graphic graphic_algorithm graphicRef140931" href="/z/d/graphic/140931.html" rel="external">algorithm 1</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with Mobitz type II second-degree AV block who are <strong>hemodynamically unstable</strong> should be urgently treated with a beta-adrenergic agent and temporary cardiac pacing (either with transcutaneous or, if immediately available, transvenous pacing). (See <a class="local">'Unstable patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with Mobitz type II second-degree AV block who are <strong>hemodynamically stable</strong> do not require urgent therapy with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> or temporary cardiac pacing. However, Mobitz type II second-degree AV block is by nature unstable and frequently progresses to third degree (complete) AV block, so patients should be continuously monitored with transcutaneous pacing pads in place in the event of clinical deterioration. (See <a class="local">'Stable patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Address reversible causes</strong> – Reversible causes of Mobitz type II second-degree AV block such as myocardial ischemia, increased vagal tone, hypothyroidism, hyperkalemia, and drugs that depress conduction should be addressed prior to determining whether permanent pacemaker implantation is required  (<a class="graphic graphic_algorithm graphicRef140930" href="/z/d/graphic/140930.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If irreversible</strong> – For patients with Mobitz type II second-degree AV block who do not have a reversible etiology, we recommend implantation of a permanent pacemaker (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We implant a dual chamber DDD pacemaker whenever possible in an effort to maintain physiologic AV synchrony.</p><p></p><p class="headingAnchor" id="H3500832566"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wenckebach, KF . Zur Analyse der unregelmässigen Pulses. Ztschr klin Med 1899; 36:181.</a></li><li><a class="nounderline abstract_t">Mobitz, W . Über die unvollständige Störung der Erregungsüberleitung zwischen Vorhof und Kammer des menschlichen Herzens. Z Gesamte Exp Med 1924; 41:180.</a></li><li class="breakAll">Narula OS. Conduction disorders in the AV transmission system. In: Cardiac Arrhythmias, Dreifus L, Likoff W (Eds), Grune and Stratton, New York 1973. p.259.</li><li class="breakAll">Peuch P. The value in intracardiac recordings. In: Cardiac Arrhythmias, Krikler D, Gododwin JF (Eds), Saunders, Philadelphia 1975. p.81.</li><li><a class="nounderline abstract_t">Puech P, Wainwright RJ. Clinical electrophysiology of atrioventricular block. Cardiol Clin 1983; 1:209.</a></li><li><a class="nounderline abstract_t">Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol 2015; 115:505.</a></li><li><a class="nounderline abstract_t">Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25:875.</a></li><li><a class="nounderline abstract_t">Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305.</a></li><li><a class="nounderline abstract_t">Rosen KM, Dhingra RC, Loeb HS, Rahimtoola SH. Chronic heart block in adults. Clinical and electrophysiological observations. Arch Intern Med 1973; 131:663.</a></li><li><a class="nounderline abstract_t">Gupta PK, Lichstein E, Chadda KD. Chronic His bundle block. Clinical, electrocardiographic, electrophysiological, and follow-up studies on 16 patients. Br Heart J 1976; 38:1343.</a></li><li><a class="nounderline abstract_t">Narula OS, Narula JT. Junctional pacemakers in man. Response to overdrive suppression with and without parasympathetic blockade. Circulation 1978; 57:880.</a></li><li><a class="nounderline abstract_t">Amat-y-Leon F, Dhingra R, Denes P, et al. The clinical spectrum of chronic His bundle block. Chest 1976; 70:747.</a></li><li><a class="nounderline abstract_t">Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:e51.</a></li><li><a class="nounderline abstract_t">Tuohy S, Saliba W, Pai M, Tchou P. Catheter ablation as a treatment of atrioventricular block. Heart Rhythm 2018; 15:90.</a></li><li><a class="nounderline abstract_t">Langendorf R, Cohen H, Gozo EG Jr. Observations on second degree atrioventricular block, including new criteria for the differential diagnosis between type I and type II block. Am J Cardiol 1972; 29:111.</a></li><li><a class="nounderline abstract_t">Goodfriend MA, Barold SS. Tachycardia-dependent and bradycardia-dependent Mobitz type II atrioventricular block within the bundle of His. Am J Cardiol 1974; 33:908.</a></li><li><a class="nounderline abstract_t">Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34:2281.</a></li><li><a class="nounderline abstract_t">Dhingra RC, Palileo E, Strasberg B, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation 1981; 64:1265.</a></li><li><a class="nounderline abstract_t">Strasberg B, Amat-Y-Leon F, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation 1981; 63:1043.</a></li></ol></div><div id="topicVersionRevision">Topic 910 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Zur Analyse der unregelmässigen Pulses</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Über die unvollständige Störung der Erregungsüberleitung zwischen Vorhof und Kammer des menschlichen Herzens</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Über die unvollständige Störung der Erregungsüberleitung zwischen Vorhof und Kammer des menschlichen Herzens</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Über die unvollständige Störung der Erregungsüberleitung zwischen Vorhof und Kammer des menschlichen Herzens</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6544636" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical electrophysiology of atrioventricular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529542" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602015" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819193" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4701376" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic heart block in adults. Clinical and electrophysiological observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1008977" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chronic His bundle block. Clinical, electrocardiographic, electrophysiological, and follow-up studies on 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/639210" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Junctional pacemakers in man. Response to overdrive suppression with and without parasympathetic blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1001051" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical spectrum of chronic His bundle block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28823599" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Catheter ablation as a treatment of atrioventricular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4550168" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Observations on second degree atrioventricular block, including new criteria for the differential diagnosis between type I and type II block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4829374" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tachycardia-dependent and bradycardia-dependent Mobitz type II atrioventricular block within the bundle of His.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801822" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7296798" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Significance of the HV interval in 517 patients with chronic bifascicular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7471363" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Natural history of chronic second-degree atrioventricular nodal block.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
